UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Estimated average burden

hours per response:

0.5

1. Name and Address of Reporting Person*PFIZER INC

(Last)

(First)

(Middle)

235 E 42ND ST

(Street)

NEW YORK

NY

10017

(City)

(State)

(Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)

05/08/2019

3. Issuer Name and Ticker or Trading Symbol

Cortexyme, Inc.

[ CRTX ]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director

10% Owner

Officer (give title below)

Other (specify below)

5. If Amendment, Date of Original Filed

(Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr.

4)

2.

Amount of Securities Beneficially Owned (Instr.

4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr.

5)

4. Nature of Indirect Beneficial Ownership (Instr.

5)

Table II - Derivative Securities Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr.

4)

2. Date Exercisable and Expiration Date

(Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr.

4)

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form: Direct (D) or Indirect (I) (Instr.

5)

6. Nature of Indirect Beneficial Ownership (Instr.

5)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Series A Redeemable Convertible Preferred Stock

(1)

(1)

Common Stock

2,360,071

(1)

D(3)

Series B Redeemable Convertible Preferred Stock

(2)

(2)

Common Stock

215,697

(2)

D(3)

Series B Redeemable Convertible Preferred Stock

(2)

(2)

Common Stock

624,205

(2)

D(3)

1. Name and Address of Reporting Person*PFIZER INC

(Last)

(First)

(Middle)

235 E 42ND ST

(Street)

NEW YORK

NY

10017

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director

10% Owner

Officer (give title below)

Other (specify below)

1. Name and Address of Reporting Person*Pfizer Ventures (US) LLC

(Last)

(First)

(Middle)

235 EAST 42ND STREET

(Street)

NEW YORK

NY

10017

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director

10% Owner

Officer (give title below)

Other (specify below)

1. Name and Address of Reporting Person*Pfizer Strategic Investment Holdings LLC

(Last)

(First)

(Middle)

235 EAST 42ND STREET

(Street)

NEW YORK

NY

10017

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director

10% Owner

Officer (give title below)

Other (specify below)

Explanation of Responses:

1. The Series A Redeemable Convertible Preferred Common Stock ("Series A Preferred Stock") consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC ("PVUS"), a controlled affiliate of Pfizer Inc. ("Pfizer"). The Series A Preferred Stock is convertible into common stock ("Common Stock") of Cortexyme, Inc. (the "Issuer") on a one-for-one basis into the number of shares of Common Stock as shown in column 3 at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock has no expiration date.

2. The Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock") consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC ("PSIH"), a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer. The Series B Preferred Stock is convertible into Common Stock on a one-for-one basis into the number of shares of Common Stock as shown in column 3 at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date.

3. Each Reporting Person disclaims ownership of securities held by each other Reporting Person, except to the extent of its respective pecuniary interest therein.

Pfizer Inc. By/s/Susan Grant, Asst. Secretary

05/08/2019

Pfizer Strategic Investment Holdings LLC By /s/ Susan Grant, Asst. Secretary

05/08/2019

Pfizer Ventures (US) LLC by /s/ Susan Grant, Secretary

05/08/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person,

see

Instruction

(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations

See

18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,

see

Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.